ABSTRACT - 599284 The disclosure relates to a composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a compound of formula (II) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein the compound of formula (I) and the compound of formula (II) are present in the composition in proportions that are synergistic in treating an HCV infection. The composition may further comprise one or two additional compounds having anti-HCV activity, such as an interferon or a ribavirin.
